The TyVOID study, published in the Lancet, measured the effectiveness of a single dose TCV in Bangladeshi children over a five-year period and confirmed the high vaccine protection (80-96%) within two years of vaccination in all children.
Three to five years after vaccination, the study found a three-fold increase in typhoid incidence in children who received TCV in 2018/2019 and those who received it in 2021, suggesting a decline in vaccine effectiveness, most pronounced in the very young. The data suggested children vaccinated at two years or older were still well protected (59-85%) at 3-5 years post vaccination however, a more significant decline in protection was seen in children vaccinated at under two years of age, suggesting that a booster dose for these children might be needed for sustained protection.
Xinxue Liu, Associate Professor of Medical Statistics and Epidemiology at the Oxford Vaccine Group, and one of the senior authors of the study, said: ‘Typhoid is a serious and life-threatening enteric fever that remains a substantial public health issue for children and adolescents in low- and middle-income countries. TCV offers the best chance to reduce the burden of typhoid, helping to reduce transmission and limiting further evolution of drug-resistant strains. This study provides additional information for policy makers on longer-term TCV protection and the importance of continued investigation and updated guidance.’
Dr Firdausi Qadri, Senior Scientist at the Infectious Diseases Division at the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), and first author on the study, said: ‘This TyVOID study followed the original TyVAC cluster randomised controlled trial population for another two and a half years after unmasking in 2021. The results indicate a decay in antibody concentrations in different age groups and suggest that a booster dose around school entry age for children vaccinated while younger than 2 years could be considered, to sustain the protection from TCV through the school years when children are at greatest risk of typhoid.’
Read the full story on the University of Oxford website.
more recommended stories
New therapies developed by Oxford experts offer online support for anxiety and post-traumatic stress disordersUrgent treatment solutions are needed for.
three key pillars to tackle antimicrobial resistance effectively — University of Oxford, Medical Sciences DivisionThe High-Level Meeting on antimicrobial resistance.
Oxford Vaccine Group marks 30 years battling ‘deadly six’ diseases with major art installation — University of Oxford, Medical Sciences DivisionThe installation was commissioned to mark.
Professor Ahmed Awarded Funding To Create World’s First Ovarian Cancer Prevention Vaccine — University of Oxford, Medical Sciences DivisionScientists at the University of Oxford,.
New research network unites Oxford University’s global fight against antimicrobial resistance — University of Oxford, Medical Sciences DivisionAntimicrobial resistance (AMR) threatens the foundation.
Study Publishes New Insights on Goblet Cell Differentiation in Colorectal Cancer — University of Oxford, Medical Sciences DivisionThe research addresses the long-recognized poor.
Four Oxford researchers win prestigious Philip Leverhulme Prizes — University of Oxford, Medical Sciences DivisionOnly 30 prizes are awarded throughout.
Kavli Oxford’s Nick Gatford Wins Image of Distinction Award in Nikon Small World Competition — University of Oxford, Medical Sciences DivisionThe Nikon Small World competition, often.
Ineos Oxford Institute awards over £2m to innovative projects to tackle antimicrobial resistance — University of Oxford, Medical Sciences DivisionThe IOI Synergy Grants scheme is.
The Translational Research Immunology Group (TRIG) celebrates huge success at International Congress of The Transplantation SocietyNora Atallah and Professor Fadi Issa.
Leave a Comment